Blog

July 2026 was another active month for the antibody biotech sector, with deal activity ranging from multibillion-dollar acquisitions and antibody licensing agreements to ADC technology deals, AI-driven discovery partnerships, and major private financings. Immunology was a major focus, alongside growing investment in next-generation ADC payloads, multispecific antibodies, and AI-powered antibody discovery.

ADLM 2026 had discussions across clinical chemistry, diagnostic immunology, microbiology, cancer diagnostics, cardiovascular disease, point-of-care testing, automation, data science, and other areas of laboratory medicine.

Identifying an antibody that binds strongly to its target is an important step in therapeutic discovery, but affinity alone does not determine whether a molecule will progress successfully through development. Antibodies with promising binding activity can still show undesirable properties related to stability, aggregation, self-interaction, nonspecific binding, solubility, or expression.

RushData offers three packages: Basic, Standard and Premium, designed to support these different stages of candidate evaluation. Each package combines high-throughput expression with a set of analytical assays and structured data outputs. The appropriate package depends on the scientific question being asked and the amount of characterization required.

For an antibody candidate, strong target binding is only part of the path toward a successful therapeutic. A molecule can show high affinity and selectivity yet encounter problems later because of poor stability, low expression, aggregation, non-specific binding, or other unfavorable biophysical properties.

Explore VHH-based biosensors for high-sensitivity detection using nanobodies in electrochemical, SPR, and optical diagnostic platforms.

Biointron’s Antibodies After Hours: BIO 2026 Reception was held at The Lion's Share in San Diego on Tuesday, June 23, 2026. Held on the second day of the BIO International Convention, we had a memorable evening of networking, drinks, and delicious appetizers with members of the biotech and pharma community at one of San Diego’s most distinctive downtown venues!

Explore how VHH antibodies stabilize protein conformations for crystallography, cryo-EM, and structural biology applications in protein structure studies.

Explore VHH antibody production strategies for molecular imaging probes, including PET, SPECT, MRI, and optical imaging applications using nanobodies.

Artificial intelligence and machine learning are expanding the number of antibody sequences that can be designed, ranked, and optimized computationally. However, a predicted antibody sequence still must be expressed and tested before researchers can determine whether it produces a functional protein with suitable binding and developability characteristics.

June 2026 included acquisitions of late-stage antibody developers, partnerships involving multispecific and AI-enabled discovery platforms, and financings supporting programs across oncology, immunology, ophthalmology, neurology, and infectious disease.

AI design still depends on experimental validationAI-driven antibody design is a process involving data curation, model development, candidate generation, computational filtering, and experimental validation.